With Merck stock (NYSE: MRK) trading near $122 in mid-2026, the company finds itself at a historic crossroads. For years, Merck has been one of the most reliable blue-chip dividend payers in the healthcare sector, powered by its ultra-blockbuster cancer immunotherapy, Keytruda. However, as the clock ticks closer to 2028—the year Keytruda's core U.S. patent expires—investors are left weighing a critical dilemma. Can Merck’s aggressive acquisition strategy, massive late-stage clinical pipeline, and upcoming subcutaneous drug reformulations successfully offset the impending patent cliff?

In this in-depth Merck stock analysis, we deconstruct the company's recent Q1 2026 financial performance, evaluate its defensive "evergreening" strategy, analyze its competitive peer landscape, and assess whether the stock's reliable dividend yield makes it a strong buy for long-term portfolios today.

The Keytruda Conundrum and the Subcutaneous Defense

To understand the trajectory of Merck stock, one must first understand the sheer scale of Keytruda (pembrolizumab). Keytruda is not just a drug; it is the single best-selling oncology asset in the world, generating more than $29 billion in annual sales. It has secured over 40 indications in the United States and 30 in Europe, acting as the bedrock of Merck's Human Health division.

However, Keytruda's core composition-of-matter patent in the United States is scheduled to expire in 2028. This upcoming milestone represents a massive "patent cliff," potentially exposing more than half of Merck’s current oncology revenue to lower-cost biosimilar competition.

To mitigate this risk, Merck is employing a highly sophisticated multi-pronged defensive strategy:

• The Subcutaneous Shift (Keytruda QLEX): Merck received key FDA approvals in late 2025 for its subcutaneous (SC) formulation of Keytruda. Rather than undergoing a multi-hour intravenous (IV) infusion at an oncology clinic, patients can receive a subcutaneous injection in a fraction of the time. Because of this massive boost in patient convenience, Merck expects to transition a significant portion of its patient base to the SC version before 2028. Crucially, the patents protecting this subcutaneous delivery technology extend well into the 2040s, providing a robust shield against immediate biosimilar erosion.
• Evergreening through Combinations: Merck is active in seeking new clinical combinations. By pairing Keytruda with novel late-stage pipeline therapies, Merck can establish new, patented standards of care that biosimilar competitors cannot easily replicate.
• The Gardasil Foundation: While Keytruda commands the headlines, Gardasil (the human papillomavirus vaccine) remains a vital multi-billion-dollar franchise. Although Gardasil faced temporary distribution headwinds in China and Japan in late 2025, the underlying demand remains exceptionally strong. As global vaccination access expands, Gardasil continues to serve as an indispensable secondary cash-flow engine for Merck.

The $70 Billion Pipeline: Aggressive M&A and New Product Launches

Merck's executive management, led by CEO Rob Davis, has repeatedly emphasized that the company has a clear "line of sight to over $70 billion of potential commercial opportunity by the mid-2030s." To achieve this ambitious target and diversify away from Keytruda dependency, Merck has deployed its robust cash reserves into high-impact mergers and acquisitions (M&A) and internal R&D.

Key pipeline pillars driving this transformation include:

1. Winrevair (Sotatercept): Approved for pulmonary arterial hypertension (PAH), Winrevair has emerged as a major commercial success. It registered an impressive $467 million in sales in Q4 2025, and its rapid adoption across clinics in 2026 indicates blockbuster status. Winrevair addresses a high-unmet-need cardiovascular market and is expected to become a multi-billion-dollar franchise in its own right.
2. The Terns Pharmaceuticals Acquisition ($5.7 Billion): Announced in early 2026, this strategic acquisition targets chronic myeloid leukemia (CML). It bolsters Merck's oncology pipeline with Terns' promising small-molecule inhibitors, offering a direct pathway to expand its hematology footprint.
3. Welireg and Ohtuvayre: Merck's newer specialized launches are scaling exceptionally well. Welireg, used for certain Von Hippel-Lindau disease-associated tumors and advanced renal cell carcinoma, posted 37% year-over-year growth, while Ohtuvayre has begun contributing meaningful early-stage revenue in the respiratory space.
4. Personalized Cancer Vaccines (PCVs): In partnership with Moderna, Merck is pioneering mRNA-4157 (V940), an investigational personalized cancer vaccine. Early 2026 clinical data readouts for its combination with Keytruda in melanoma showed phenomenal long-term recurrence-free survival rates, sparking strong optimistic sentiment on Wall Street.

Through these strategic moves, Merck is systematically building a diversified portfolio of growth drivers spanning cardiovascular disease, immunology, hematology, and next-generation oncology.

Financial Performance: Analyzing Merck's Q1 2026 Earnings

Merck's Q1 2026 earnings report, released on April 30, 2026, highlighted the company's strong operational execution and resilient product portfolio.

• Worldwide Sales: Merck posted Q1 sales of $16.3 billion, driven by double-digit underlying growth in core oncology therapies and animal health.
• Adjusted Earnings Per Share (EPS): While GAAP earnings reflected temporary paper losses due to one-time business development and M&A integration charges, non-GAAP adjusted EPS came in at -$1.28, comfortably beating conservative consensus analyst estimates of -$1.48 to -$1.51.
• Revised 2026 Guidance: Buoyed by strong early-year performance, Merck raised its full-year 2026 sales guidance to a range of $65.8 billion to $67.0 billion (up from previous guidance). It also projected full-year non-GAAP EPS to land between $5.04 and $5.16.

This earnings beat and positive forward revision reassured the market that Merck's commercial engine is operating at full capacity. Despite high-profile R&D spending and the integration costs of acquisitions like Terns and Cidara, operational margins remain robust.

Balance Sheet Strength and Debt Management

A major consideration for Merck stock investors is the health of the balance sheet, particularly given the company's aggressive acquisition program.

Total net debt currently stands at approximately $50 billion. While this number might seem intimidating at first glance, it must be evaluated alongside Merck's substantial cash-generation capabilities. The company generates roughly $27 billion in annual EBITDA. Consequently, its net debt-to-EBITDA leverage ratio remains comfortably below 2.0x—a level that major credit agencies consider highly manageable for a stable, cash-rich pharmaceutical giant. Merck retains ample borrowing capacity to pursue further science-led business development without risking its investment-grade credit rating.

Dividend Yield and Payout Safety: An Income Investor's Dream?

For decades, Merck stock has been favored by income-focused investors for its reliable dividend payments.

Currently trading around $122.41, Merck offers a highly attractive forward dividend yield of approximately 2.6%. The company has a long-standing history of consistent dividend growth, a trend that continued through 2025 and 2026.

Is the dividend safe heading into the patent cliff?

With projected 2026 non-GAAP EPS of $5.04 to $5.16, Merck's dividend payout ratio sits safely below 65%. This conservative payout ratio provides a massive safety buffer. Even if the company faces transient earnings pressure as Keytruda transitions to generic competition in the late 2020s, Merck has more than enough financial headroom to maintain, and likely continue increasing, its annual dividend distributions.

Valuation and Peer Comparison

To determine if Merck stock is currently a buy, hold, or sell, it is helpful to contrast its valuation with other major players in the pharmaceutical sector:

• The Growth Darlings (Eli Lilly & Novo Nordisk): Driven by the global obesity-drug boom, players like Eli Lilly (LLY) and Novo Nordisk (NVO) trade at steep forward P/E multiples, often exceeding 35x to 40x. While their growth is phenomenal, they carry significant valuation risk.
• The Legacy Value Traps (Pfizer & Bristol Myers Squibb): On the other end of the spectrum, companies like Pfizer (PFE) and Bristol Myers Squibb (BMY) trade at low single-digit or low double-digit earnings multiples. However, they struggle with severe post-COVID revenue declines and weaker clinical pipelines.
• The Balanced Sweet Spot (Merck): Merck trades at a forward P/E of roughly 24x based on 2026 non-GAAP earnings. This represents a highly attractive middle ground. It is far cheaper than the high-flying weight-loss stock market darlings, yet represents a vastly superior pipeline and growth narrative than the struggling legacy players.

Wall Street analysts share this constructive view. The consensus rating on MRK remains a "Strong Buy" with a median 12-month analyst price target of $135.00, implying a realistic 10% to 15% upside from current trading levels.

Key Risks Facing Merck Stock

No investment is entirely risk-free. Before adding Merck stock to your portfolio, consider these potential headwinds:

• Inflation Reduction Act (IRA) Price Controls: Starting in 2026, the U.S. government's Medicare price-setting initiatives represent a structural shift for the pharmaceutical industry. Keytruda is widely expected to face price negotiations, which could pressure profit margins in the massive domestic market even before biosimilars arrive.
• Clinical Trial Hurdles: Bringing novel therapies to market is incredibly difficult. If high-profile Phase 3 candidates—including candidates acquired via Terns or Cidara—suffer clinical setbacks or fail to win FDA approval, Merck's long-term pipeline targets could be delayed.
• Execution on the Subcutaneous Shift: The success of Merck's patent cliff defense depends on its ability to rapidly shift clinical practice toward Keytruda QLEX. If insurers or clinical networks resist this transition, biosimilar competition could erode Keytruda's market share faster than expected.

Frequently Asked Questions (FAQ)

When does Merck's Keytruda patent expire?

The core composition-of-matter patent for Keytruda in the United States is set to expire in 2028. However, Merck has developed an extensive network of secondary patents—including those covering its newly approved subcutaneous (SC) formulation—which could protect various aspects of the Keytruda franchise through 2042.

What is the dividend yield of Merck stock?

At a stock price of approximately $122.41, Merck (NYSE: MRK) offers a forward dividend yield of about 2.6%. The company has a consistent track record of raising its dividend annually, making it highly attractive for conservative, income-oriented portfolios.

Did Merck beat expectations in its Q1 2026 earnings?

Yes. On April 30, 2026, Merck reported Q1 worldwide sales of $16.3 billion and raised its full-year 2026 sales guidance to $65.8 billion - $67.0 billion. Non-GAAP adjusted EPS of -$1.28 beat Wall Street's expectations, driven by resilient oncology sales and strong veterinary health performance.

Is Merck stock a safe retirement investment?

Historically, Merck is considered a highly defensive blue-chip stock. Its strong balance sheet, manageable debt levels, robust cash flow, and reliable dividend yield provide classic defensive characteristics. While the 2028 patent cliff represents a risk, the company's $70 billion mid-2030s pipeline target makes it a resilient long-term holding.

Conclusion: Is Merck Stock a Buy, Sell, or Hold?

Merck & Co., Inc. continues to demonstrate why it is a premier name in global healthcare. While the impending 2028 Keytruda patent cliff is a legitimate concern, Merck is not a passive bystander. Through its proactive subcutaneous evergreening defense, stellar launch momentum for drugs like Winrevair, and aggressive pipeline-building M&A, the company is actively preparing to offset potential revenue losses.

With a sustainable dividend yield of 2.6%, robust cash flows, and a reasonable valuation compared to high-flying pharmaceutical peers, Merck stock presents an attractive blend of income security and defensive growth. For long-term investors looking to anchor their portfolios with a high-quality, dividend-paying healthcare giant, Merck stock remains a compelling "Buy."